Your AI-Trained Oncology Knowledge Connection!
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy reported with ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).
Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.
Marcus Albertsmeier, MD, surgeon at Ludwig Maximilian University of Munich, discusses the effect of radiation therapy on local recurrence and overall survival for patients with soft tissue sarcoma.
Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.
John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses pacritinib in patients with myelofibrosis.
Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy in the treatment landscape of multiple myeloma.
Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.
Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.
Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.
Jennifer A. Woyach, MD, an associate professor of Medicine in the Division of Internal Medicine at The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of the CD19-directed antibody MOR208 in combination with lenalidomide (Revlimid) or ibrutinib (Imbruvica) in patients with CLL.
Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.
Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.
Martin S. Tallman, MD, hematologic oncologist, chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the state of the science with regards to treatment of patients with acute myeloid leukemia (AML).
Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.
Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.
Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.
Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.
Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.
David J. Straus, MD, an internist and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials in the field of Hodgkin lymphoma.
Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses MRI fusion-guided biopsy in patients with prostate cancer.
Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses how ATF4 targets RET for degradation and is a candidate tumor suppressor gene in medullary thyroid cancer.
Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, chairman of the Japanese Clinical Oncology Group, discusses the future of bursectomy and omentectomy for patients with gastric cancer.
Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.
Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).
Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.
Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses some of the ongoing challenges researchers need to tackle in the field of ovarian cancer.
Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for patients with BRAF-mutant melanoma.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses biomarkers in head and neck cancer.
Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.
